Abstract
Cardiovascular diseases are the leading cause of death, and dyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease. During the last several decades, development of drugs that reduce low density lipoprotein-cholesterol has been the focus in the treatment and prevention of dyslipidemia and cardiovascular diseases. In addition, statins and other cholesterol-reducing drugs have been the standard of treatment for dyslipidemia. Triglyceride (TG)-rich lipoproteins are also a significant risk factor for atherosclerosis and cardiovascular diseases, and pharmacological strategies to control TG-rich lipoproteins are now attracting much interest. In this review, mediators of lipoprotein metabolism and current therapeutic strategies with the formulation designs are discussed and new candidate therapeutic targets are presented.
| Original language | English |
|---|---|
| Pages (from-to) | 233-241 |
| Number of pages | 9 |
| Journal | Journal of Pharmaceutical Investigation |
| Volume | 48 |
| Issue number | 3 |
| DOIs | |
| State | Published - 1 May 2018 |
Bibliographical note
Publisher Copyright:© 2017, The Korean Society of Pharmaceutical Sciences and Technology.
Keywords
- Cholesterol
- Drug delivery system
- Dyslipidemia
- Lipoprotein
- Triglyceride
